Gummy dosage forms comprising gummy compositions for nutritional supplementation, methods for providing nutritional supplementation, and kits comprising gummy compositions for nutritional supplementation are disclosed. Such gummy compositions for nutritional supplementation may provide improved patient compliance relative to non-gummy compositions for nutritional supplementation. These gummy compositions can be used to administer one or more vitamins, minerals, or trace elements.

Gummy dosage forms comprising gummy compositions for nutritional supplementation, methods for providing nutritional supplementation, and kits comprising gummy compositions for nutritional supplementation are disclosed. Such gummy compositions for nutritional supplementation may provide improved patient compliance relative to non-gummy compositions for nutritional supplementation. These gummy compositions can be used to administer one or more vitamins, minerals, or trace elements.

The present patent application relates to novel polyunsaturated fatty acid salt (PUFA salts) solid formulations.

The present patent application relates to novel polyunsaturated fatty acid salt (PUFA salts) solid formulations.

Provided are beverage compositions containing non-polar compounds that retain one or more organoleptic properties after formulation as compared to beverage compositions that do not contain the non-polar compounds. Also provided are methods for producing beverage compositions that contain non-polar compounds such as essential fatty acids, including omega-3 fatty acids, omega-6 fatty acids, conjugated fatty acids, and other fatty acids; phytochemicals, including phytosterols and carotenoids; oil soluble vitamins; alpha lipoic acid; other oils; and coenzymes, including coenzyme Q10, and other oil-based additives.

Provided are beverage compositions containing non-polar compounds that retain one or more organoleptic properties after formulation as compared to beverage compositions that do not contain the non-polar compounds. Also provided are methods for producing beverage compositions that contain non-polar compounds such as essential fatty acids, including omega-3 fatty acids, omega-6 fatty acids, conjugated fatty acids, and other fatty acids; phytochemicals, including phytosterols and carotenoids; oil soluble vitamins; alpha lipoic acid; other oils; and coenzymes, including coenzyme Q10, and other oil-based additives.

The present invention relates to a novel emulsion structured in an isometric crystalline network of cellulose derivatives where the emulsion comprises Omega-3 fatty acids homogeneously distributed in the same. The emulsion of the invention has been designed to have greater stability, bioavailability and gastro-resistance and may be used in special medical foods, nutritional supplements, sports nutrition, enteral nutrition or child nutrition, amongst others.

The present invention relates to a gallstone solubilizing agent, comprising ursodeoxycholic acid (UDCA) or a pharmaceutically acceptable salt thereof; omega-3 fatty acid; and an excipient, the gallstone solubilizing agent resulting in a process which prevents cholesterol gallstones from being formed or causes cholesterol gallstones to be dissolved, a pharmaceutical composition comprising the same, and a health functional food composition comprising the same. A pharmaceutical composition prepared to have UDCA and omega-3 fatty acid at an optimal content ratio allows cholesterol to remain in a dissolved state without forming crystals, and thus results in a process which prevents cholesterol gallstones from being formed or causes cholesterol gallstones to be dissolved, thereby exhibiting increased effects of preventing or treating cholesterol gallstones.

The present invention relates to a gallstone solubilizing agent, comprising ursodeoxycholic acid (UDCA) or a pharmaceutically acceptable salt thereof; omega-3 fatty acid; and an excipient, the gallstone solubilizing agent resulting in a process which prevents cholesterol gallstones from being formed or causes cholesterol gallstones to be dissolved, a pharmaceutical composition comprising the same, and a health functional food composition comprising the same. A pharmaceutical composition prepared to have UDCA and omega-3 fatty acid at an optimal content ratio allows cholesterol to remain in a dissolved state without forming crystals, and thus results in a process which prevents cholesterol gallstones from being formed or causes cholesterol gallstones to be dissolved, thereby exhibiting increased effects of preventing or treating cholesterol gallstones.

The method of producing a lipid composition comprises an extraction treatment step to extract a lipid comprised in a hydrated raw material by using an extraction solvent comprising a polar solvent and a nonpolar solvent, and a separation treatment step to separate an extract solution obtained in the extraction treatment step into a polar solvent phase comprising a first lipid fraction and a nonpolar solvent phase comprising a second lipid fraction.